SLNO
Soleno Therapeutics Inc
Halal Rating :
Last Price
$46.80
Last updated:
Market Cap
-
7D Change
8.69%
1 Year Change
-2.52%
Company Overview
Industries
Exchange
Next Earnings Date
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Their lead candidate, DCCR (Diazoxide Choline), is being developed for the treatment of Prader-Willi syndrome (PWS), a rare genetic disorder that causes life-threatening obesity.
The company is currently in the pre-revenue stage, focusing primarily on research and development activities to advance their therapeutic pipeline.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Soleno Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.